New York State Common Retirement Fund Increases Stock Position in Phreesia, Inc. $PHR

New York State Common Retirement Fund boosted its holdings in Phreesia, Inc. (NYSE:PHR) by 727.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 136,856 shares of the company’s stock after buying an additional 120,309 shares during the period. New York State Common Retirement Fund’s holdings in Phreesia were worth $3,219,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Loomis Sayles & Co. L P bought a new position in Phreesia during the 2nd quarter valued at about $34,162,000. Capricorn Fund Managers Ltd purchased a new position in shares of Phreesia during the third quarter valued at approximately $11,395,000. Cambiar Investors LLC bought a new position in Phreesia during the second quarter valued at approximately $10,674,000. Greenhouse Funds LLLP boosted its holdings in Phreesia by 12.5% in the second quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company’s stock worth $94,637,000 after purchasing an additional 368,352 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Phreesia by 205.4% in the 2nd quarter. Marshall Wace LLP now owns 418,484 shares of the company’s stock worth $11,910,000 after purchasing an additional 281,454 shares during the period. 92.10% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Balaji Gandhi sold 8,009 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $136,233.09. Following the completion of the transaction, the chief financial officer owned 156,231 shares of the company’s stock, valued at approximately $2,657,489.31. This represents a 4.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $44,260.02. Following the completion of the sale, the senior vice president owned 160,238 shares of the company’s stock, valued at $2,725,648.38. The trade was a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 60,766 shares of company stock valued at $1,013,817. Insiders own 5.50% of the company’s stock.

Phreesia Stock Performance

Shares of PHR opened at $12.22 on Friday. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $16.40 and a two-hundred day simple moving average of $21.92. The stock has a market cap of $736.74 million, a price-to-earnings ratio of -122.19 and a beta of 0.65. Phreesia, Inc. has a 52 week low of $12.06 and a 52 week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm’s revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.25) EPS. On average, analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PHR shares. Canaccord Genuity Group lowered their price target on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, December 9th. Mizuho set a $22.00 target price on Phreesia in a report on Wednesday. Zacks Research cut Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Barclays cut their price target on Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, December 16th. Finally, Wall Street Zen cut shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.41.

Phreesia Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.